RS62932B1 - Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a - Google Patents

Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a

Info

Publication number
RS62932B1
RS62932B1 RS20220142A RSP20220142A RS62932B1 RS 62932 B1 RS62932 B1 RS 62932B1 RS 20220142 A RS20220142 A RS 20220142A RS P20220142 A RSP20220142 A RS P20220142A RS 62932 B1 RS62932 B1 RS 62932B1
Authority
RS
Serbia
Prior art keywords
fluticasone propionate
nanocrystals
nanosuspension
suspension
phase
Prior art date
Application number
RS20220142A
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Michel Bukowski
Akshay Nadkarni
José L Boyer
Brigitte Duquesroix-Chakroun
Tomas Navratil
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of RS62932B1 publication Critical patent/RS62932B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
RS20220142A 2019-07-23 2020-07-21 Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a RS62932B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02
EP20186965.8A EP3769753B1 (en) 2019-07-23 2020-07-21 Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Publications (1)

Publication Number Publication Date
RS62932B1 true RS62932B1 (sr) 2022-03-31

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220142A RS62932B1 (sr) 2019-07-23 2020-07-21 Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a

Country Status (23)

Country Link
US (3) US11406596B2 (enExample)
EP (1) EP3769753B1 (enExample)
JP (2) JP7021301B2 (enExample)
KR (1) KR20220038443A (enExample)
CN (2) CN115120557B (enExample)
AU (1) AU2020317084A1 (enExample)
CA (1) CA3145055A1 (enExample)
CY (1) CY1124930T1 (enExample)
DK (1) DK3769753T3 (enExample)
ES (1) ES2905793T3 (enExample)
HR (1) HRP20220165T1 (enExample)
HU (1) HUE057416T2 (enExample)
LT (1) LT3769753T (enExample)
MD (1) MD3769753T2 (enExample)
MX (1) MX420447B (enExample)
PH (1) PH12022550003A1 (enExample)
PL (1) PL3769753T3 (enExample)
PT (1) PT3769753T (enExample)
RS (1) RS62932B1 (enExample)
SI (1) SI3769753T1 (enExample)
SM (1) SMT202200082T1 (enExample)
TW (1) TWI864053B (enExample)
WO (1) WO2021014348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020317084A1 (en) * 2019-07-23 2022-03-03 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0639070T4 (da) 1992-05-06 2010-12-13 Alcon Lab Inc Anvendelse af borat-polyolkomplekser til ophtalmiske præparater
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
DK3517541T3 (da) 2012-05-08 2020-09-07 Nicox Ophthalmics Inc Polymorf form af fluticasonpropionat
CA2893654A1 (en) * 2012-12-17 2014-06-26 Glaxo Group Limited Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑
AU2020317084A1 (en) * 2019-07-23 2022-03-03 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Also Published As

Publication number Publication date
PT3769753T (pt) 2022-02-15
AU2020317084A1 (en) 2022-03-03
WO2021014348A1 (en) 2021-01-28
TW202116326A (zh) 2021-05-01
US11406596B2 (en) 2022-08-09
EP3769753A1 (en) 2021-01-27
SI3769753T1 (sl) 2022-04-29
MD3769753T2 (ro) 2022-04-30
SMT202200082T1 (it) 2022-03-21
MX420447B (es) 2025-02-10
JP7494230B2 (ja) 2024-06-03
CN111821261B (zh) 2022-07-26
DK3769753T3 (da) 2022-01-31
HUE057416T2 (hu) 2022-05-28
US20210023001A1 (en) 2021-01-28
CN115120557A (zh) 2022-09-30
EP3769753B1 (en) 2021-11-17
JP2022062172A (ja) 2022-04-19
HRP20220165T1 (hr) 2022-04-29
ES2905793T3 (es) 2022-04-12
JP7021301B2 (ja) 2022-02-16
CN115120557B (zh) 2024-05-07
MX2022000928A (es) 2022-02-22
KR20220038443A (ko) 2022-03-28
PH12022550003A1 (en) 2022-11-14
JP2021017449A (ja) 2021-02-15
CN111821261A (zh) 2020-10-27
US20220241296A1 (en) 2022-08-04
US20220323352A1 (en) 2022-10-13
CY1124930T1 (el) 2023-01-05
TWI864053B (zh) 2024-12-01
CA3145055A1 (en) 2021-01-28
PL3769753T3 (pl) 2022-04-04
LT3769753T (lt) 2022-05-10

Similar Documents

Publication Publication Date Title
JP7455917B2 (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
EP2978409B1 (en) Ophthalmic composition, method for preparing the same, and use of the same
KR101890503B1 (ko) 안구 장애의 치료를 위한 막-부착성 자가-조립된 시스템
US20220323352A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN107613985A (zh) 含有糖皮质激素的纳米微粒的水性悬浮液剂
JP7716996B2 (ja) 薬剤を含む水性組成物のpHを安定化させるための方法
CN104814924A (zh) 一种布佐林胺脂质体眼用制剂及其制备方法
CN104721136A (zh) 一种布佐林胺眼用纳米混悬剂及其制备方法
KR20100129263A (ko) 다당류 미립자상 겔 함유 수분산체 및 그 제조 방법
HK40077423A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40038382B (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40038382A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
HK40077423B (zh) 用於制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
JPWO2016039422A1 (ja) 点眼用懸濁製剤
HK40097477A (en) Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
WO2022195382A1 (en) A stable ophthalmic nanosupension of brinzolamide
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系
HK1234413A1 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders